

DRS DU BUISSON, KRAMER, SWART, BOUWER INC.				
REFERRING DOCTOR				
COPY DOCTOR				

PLACE BARCODE HERE

CLINICAL DIAGNOSIS/		MEDICAL AID	PLAN					
MEDICATION		MEDICAL AID NO.	DEP. CODE					
ICD-10 CODES		MEDICAL AID AUTH.	STAT ROUTINE					
PATIENT DETAI	LS	PERSON RESPONSIBLE FOR ACCOUNT (GUARANTOR)						
ID NUMBER		GUARANTOR ID NUMBER						
SURNAME	TITLE	SURNAME						
INITIALS & FIRST NAME	AGE	INITIALS & FIRST NAME	TITLE					
DATE OF BIRTH	D D M M Y Y Y Y SEX ASSIGNED M F	POSTAL ADDRESS						
HOSPITAL/ FOLIO NO.			POSTAL CODE					
CELL	CELL (H)		(H)					
(W)		(W)						
EMAIL		EMAIL						
PATIENT/GUARDIAN SIGNATURES: I confirm acceptance of the informed consent available at ampath.co.za. I verify that all personal information is correct. GUARANTOR'S SIGNATURE: I consent to the requested tests and guarantee payment thereof. I consent that ICD10 codes may be provided to my medical aid as per statutory requirements on my account.								
PHLEBOTOMY SITE COLL DATE COLL DATE COLL COLL THYROID Y N PREGNANT Y N REC. D D M M Y Y Y Y Y THYROID Y N COAGULANT Y N REC. TIME BY								
HOSPITAL PATIEN	IT Y N NO OF TUBES DRAWN S01 S02 E01 E02 H	EP CIT FLU	MICRO / TEST COUNT					

PERSONALISED MEDICATION TEST

Pharmacogenomics

PHARMA



Signature of patient's representative:

INFORMED CONSENT FOR PHARMACOGENETIC (PGx) TESTING

I,	or, if applicable,	lawfully re	presenting			
	, who is a child younger than	12 years old or an individual lack	king sufficient mental			
capacity to understand the pha	armacogenetic test, hereby ack	knowledge and consent to the foll	owing:			
Purpose of Genetic Testing: I understand that I/the patient will be undergoing a pharmacogenetic test to assess how my/the patient's genetic makeup may influence my/their response to certain medications. This test aims to provide clinical decision support to healthcare professionals involved in my/the patient's care.						
-	kit to the best of my/their abilitie	s carefully followed the specimenes (if applicable) and consent that	-			
Data Transmission to GenXys Health Care Systems Inc: I acknowledge that the genetic results of the harmacogenetic test, as well as my/the patient's personal health information, will be transmitted to GenXys based in Canada. I understand that Canandian data protection legislation is similar to the South African Protection of Personal information Act 4 of 2013 ("POPIA") and that GenXys has sufficient Information Technology standards in place to safegual and protect my/the patient's personal information, as required by section 72 of POPIA. This information will only be used for purpose referred to in clause 1. I understand that GenXys will not de-identify my/the patient's health information/geneticate but may not use it for any other commercial application, unless I/the patient grant explicit consent.						
utmost confidentiality. Only au intended purpose. GenXys is s Protection of Personal Informa	thorised personnel will have ac subject to similar health data pr	and personal health information cess to this information, and it wirvacy regulations (PIPEDA, GDP ealth Act 61 of 2003, Health Profe Act 38 of 2005.	ll be used exclusively for the R & HIPAA) as South Africa's			
potential risk of unauthorised a	access or data breaches still re	nade to maintain the security of m mains. GenXys has implemented IA in order to lawfully process and	measures to minimise these			
_		patient has the right to withdraw thout affecting my/the patient's cu				
		the opportunity to ask questions ting, and all my/the patient's quer				
		ent's physician and Drs Du Buiss in terms of section 6 of the Nation				
	it to undergo the pharmacogen formation to GenXys, for the sp	etic test and agree to the transmi pecified purposes.	ssion of my/the patient's			
Patient's Signature:		Date:				
or (if applicable)						
Full names and surname of	patient:					
Full names and surname of	patient's representative:					
Relationship to patient:						

____ Date: ____